MedTrace Logo

Iperia/Sentus QP Study

NCT02181686 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2015-07-15

No results posted yet for this study

Summary

The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.

Conditions

Sponsors & Collaborators

  • Biotronik SE & Co. KG

    lead INDUSTRY

Principal Investigators

  • Werner Jung, Prof. Dr. · Schwarzwald-Baar Klinikum Villingen-Schwenningen, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Austria
  • Denmark
  • Finland
  • Germany
  • Italy
  • Latvia
  • Netherlands
  • Singapore
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02181686 on ClinicalTrials.gov